medigraphic.com
A partir del año 2010, la Revista Oficial del INER cambió a NCT (Neumología y Cirugía de Tórax)

 Ver actualización

2006, Number 3

<< Back Next >>

Rev Inst Nal Enf Resp Mex 2006; 19 (3)

Increase of myeloperoxidase activity in patients with asthma associated to diabetes mellitus type 2. An indicator of homeostatic disequilibrium

Sierra VMP, Mendoza ARS, Fernández VM, San Miguel MGF, Hicks GJJ

Language: Spanish
References: 22
Page: 201-205
PDF size: 80.14 Kb.


ABSTRACT

Background: The activity of the enzyme myeloperoxidase (MPO, EC 1.11.1.7), in plasma has been related to several chronic-degenerative diseases such as asthma and diabetes mellitus which have in common a chronic inflammatory condition. Several reactive species of oxygen are generated during inflammation, including hypochlorous acid, which is a product of MPO.
Objective: To prove that asthma and diabetes mellitus, in which there is oxidative stress, present a cumulative metabolic response that can be measured by an increase of MPO, as a marker of oxidative damage.
Methods: The activity of MPO was measured in the plasma of a control group of 31 healthy volunteers and in three groups of patients: a) 13 asthmatics, b) 29 diabetics, c) 6 asthmatics and diabetics.
Results: In patients with both diseases, asthma and diabetes mellitus, there was a significant increase in the activity of the enzyme MPO (65.1 ± 11.2 U*; p ‹ 0.05). The activity of MPO was similar in the control group (37.6 ± 3.2 U*), the asthma group (35.9 ± 5.2 U*) and the diabetics (32.6 ± 3.3 U*).
Conclusions: The coexistence of asthma and diabetes mellitus, both chronic-degenerative diseases, inincreases the possibility of tissue damage due to the generation of oxygen reactive species that overwhelms the antioxidant defenses of the body, augmenting the oxidative stress and inducing secondary tissue damage and homeostatic disequilibrium.
*U= U/mg of protein


REFERENCES

  1. Wu W, Samoszuk MK, Comhair SA, et al. Eosinophils generate brominating oxidants in allergen-induced asthma. J Clin Invest 2000;105:1455-1463.

  2. Hicks GJJ, Sierra VMP, Olivares-Corichi IM, Torres RJD, Guzmán-Grenfell AM. Estrés oxidante en asma. Rev Inst Nal Enf Resp Mex 2005;18:70-78.

  3. Sierra VMP, Guzmán-Grenfell AM, Olivares-Corichi IM, Torres RJD, Hicks GJJ. Participación de las especies reactivas del oxígeno (ERO) en las enfermedades pulmonares. Rev Inst Nal Enf Resp Mex 2004;17:135-148.

  4. Abul H, Abul A, Khan I, Mathew TC, Ayed A, Al-Athary E. Levels of IL-8 and myeloperoxidase in the lungs of pneumonia patients. Mol Cell Biochem 2001;217:107-112.

  5. Mathy-Hartert M, Damas P, Nys M, et al. Nitrated proteins in bronchoalveolar lavage fluid of patients at risk of ventilator-associated bronchopneumonia. Eur Respir J 2000;16:296-301.

  6. Barnes PJ. Reactive oxygen species and airway inflammation. Free Radic Biol Med 1990;9:235-243.

  7. Nadeem A, Chhabra SK, Masood A, Raj HG. Increased oxidative stress and altered levels of antioxidants in asthma. J Allergy Clin Immunol 2003;111:72-78.

  8. Monteseirin J, Bonilla I, Camacho J, Conde J, Sobrino F. Elevated secretion of myeloperoxidase by neutrophils from asthmatic patients: the effect of immunotherapy. J Allergy Clin Immunol 2001;107: 623-626.

  9. Cantin AM, North SL, Fells GA, Hubbard RC, Crystal RG. Oxidant-mediated epithelial cell injury in idiopathic pulmonary fibrosis. J Clin Invest 1987; 79:1665-1673.

  10. Ricciardolo FL, Caramori G, Ito K, et al. Nitrosative stress in the bronchial mucosa of severe chronic obstructive pulmonary disease. J Allergy Clin Immunol 2005;116:1028-1035.

  11. Keatings VM, Barnes PJ. Granulocyte activation markers in induced sputum: comparison between chronic obstructive pulmonary disease, asthma, and normal subjects. Am J Respir Crit Care Med 1997;155:449-453.

  12. Podrez EA, Abu-Soud HM, Hazen SL. Myeloperoxidase-generated oxidants and atherosclerosis. Free Radic Biol Med 2000;28:1717-1725.

  13. Carr AC, McCall MR, Frei B. Oxidation of LDL by myeloperoxidase and reactive nitrogen species: reaction pathways and antioxidant protection. Arterioscler Thromb Vasc Biol 2000;20:1716-1723.

  14. Hazen SL, Heinecke JW. 3-Chlorotyrosine, a specific marker of myeloperoxidase-catalyzed oxidation, is markedly elevated in low density lipoprotein isolated from human atherosclerotic intima. J Clin Invest 1997;99:2075-2081.

  15. Vita JA, Brennan M-L, Gokce N, et al. Serum myeloperoxidase levels independently predict endothelial dysfunction in humans. Circulation 2004;110:1134-1139.

  16. Baldus S, Heeschen C, Meinertz T, et al; and the CAPTURE Investigators. Myeloperoxidase serum levels predict risk in patients with acute coronary syndromes. Circulation 2003;108:1440-1445.

  17. Andrews PC, Krinsky NI. Quantitative determination of myeloperoxidase using tetramethylbenzidine as substrate. Anal Biochem 1982;127:346-350.

  18. Eiserich JP, Baldus S, Brennan ML, et al. Myeloperoxidase, a leukocyte-derived vascular NO oxidase. Science 2002;296:2391-2394.

  19. Baldus S, Eiserich JP, Mani A, et al. Endothelial transcytosis of myeloperoxidase confers specificity to vascular ECM proteins as targets of tyrosine nitration. J Clin Invest 2001;108:1759-1770.

  20. Carr AC, Myzak MC, Stocker R, McCall MR, Frei B. Myeloperoxidase binds to low-density lipoprotein: potential implications for atherosclerosis. FEBS Lett 2000;487:176-180.

  21. Heinecke JW, Li W, Daehnke HL 3rd, Goldstein JA. Dityrosine, a specific marker of oxidation, is synthesized by the myeloperoxidase-hydrogen peroxide system of human neutrophils and macrophages. J Biol Chem 1993;268:4069-4077.

  22. Fu X, Kassim SY, Parks WC, Heinecke JW. Hypochlorous acid oxygenates the cysteine switch domain of pro-matrilysin (MMP-7). A mechanism for matrix metalloproteinase activation and atherosclerotic plaque rupture by myeloperoxidase. J Biol Chem 2001;276: 41279-41287.




2020     |     www.medigraphic.com